Oxygen Biotherapeutics now has a clinical development pipeline which includes seven indications for Oxycyte(TM) emulsion. Oxycyte is the Company’s perfluorocarbon (PFC) therapeutic oxygen carrier. The new Oxycyte pipeline includes: Traumatic Brain Injury, Carbon Monoxide Poisoning, Surgical Iatrogenic Air Embolism, Spinal Cord Injury, Organ Preservation, Decompression Sickness, and Sickle Cell Crisis.

The company has also reported that its topical pipeline includes six additional indications in development for the Oxycyte Gel. The first use of the Dermacyte Gel is for a cosmetic line that is now available for pre-orders via the BuyDermacyte.com website, with product shipment expected in about four weeks. Other uses include treatment for Wounds, Burns, Acne, Rosacea, Cell Treatment after Radiation Therapy, and Erectile Dysfunction. Oxygen Biotherapeudics is also working on two additional uses for Oxycyte Compounds, including a ventilation device called VitaVent and a Deep Immersion Fluorocarbon Treatment for severe burns.

Oxygen Biotherapeutics CEO Chris Stern commented on the

Oxygen Biotherapeutics, Inc. (OTCBB: OXBO) announced that they have a meeting scheduled for October with the Food and Drug Administration about any remaining issues with a planned trial for its Oxycyte drug.

Oxycyte is a perfluorocarbon oxygen carrier. Its proposed use is to help with traumatic brain injury. Oxygen Bio and the country’s standards agency have tentatively set Oct. 20 as the date.

“At that meeting, we will be extensively prepared to resolve any remaining issues and concerns the FDA may have,” said company Chairman and CEO Chris J. Stern. “We view this as a positive development, as the agency has also offered to review the Company’s overall development plan. This may contribute to reducing regulatory risk at future stages such as Phase III.”

Trials would be in the Phase 2b stage. The company would conduct a multi-center, double-blind, placebo-controlled study of up to 300 patients. 200 patients will be allowed for enrollment

As previously announced in June, Synthetic Blood International has changed its name to Oxygen Biotherapeutics, Inc. effective today. The company will continue to trade on the Over-the-Counter Bulletin Board but with a new symbol. Starting with the opening of trading today, the company’s new trading symbol will be OXBO.

The company’s focus will continue to be the same. Oxygen Biotherapeutics is dedicated to transforming patient care by developing advanced, oxygen-based therapies using Oxycyte®, the company’s perfluorocarbon (PFC) therapeutic oxygen carrier, and other solutions. The company believes Oxycyte has the potential for use in multiple indications, including traumatic brain injury, sickle-cell pain crisis, decompression sickness, stroke, heart attack, and wound treatment. Based on the number of incidences and need for treatment, the company estimates that the worldwide market potential for all biotherapeutic uses of oxygen therapies could be up to the double-digit millions.

Commenting on the new corporate name, chairman and CEO Chris

The Department of Defense has awarded Synthetic Blood International a number of grants totaling more than $5.3 million. The funding from these grants will be used to study clinical applications for Oxycyte®, the company’s perfluorocarbon therapeutic oxygen carrier.

The company describes Oxycyte as an oxygen-carrying intravenous emulsion that can carry five times more oxygen than hemoglobin, making it an effective means of transporting oxygen to tissues and carbon dioxide to the lungs for disposal. New applications of oxygen therapy include stroke, myocardial infarction, and certain malignant diseases.

In brief, the grants will be used for the following studies: $1.3 million will be used for the treatment and prevention of decompression sickness with Oxycyte; $1.6 million was made for support of research into Oxycyte’s ability to treat/prevent organ damage from arterial gas embolism over a period of three years; $1.2 million will be utilized in ongoing studies of perfluorocarbon emulsions in the